Nilotinib
Back to searchMolecule Structure
Scientific Name
Nilotinib
Description of the Drug
Nilotinib is a kinase inhibitor used for the chronic phase treatment of Chronic Myeloid Leukemia (CML) that is Philadelphia chromosome positive and for the treatment of CML that is resistant to therapy containing imatinib.
Source: DrugBank Online – DrugBank.com. Retrieved 2023-03-10 from
http://www.drugbank.ca/drugs/DB04868
http://www.drugbank.ca/drugs/DB04868
Brand Name(s)
Tasigna
Company Owner(s)
Novartis Pharmaceuticals Corp
Mechanism(s) Of Action
| Target Name | Target Type | Action Type | Target ChEMBL ID |
|---|---|---|---|
| Tyrosine-protein kinase ABL | SINGLE PROTEIN | INHIBITOR | CHEMBL1862 |
| Bcr/Abl fusion protein | CHIMERIC PROTEIN | INHIBITOR | CHEMBL2096618 |
Clinical Trial(s)
Unichem Links
| Atlas | Nilotinib | ||
| SureChEMBL | SCHEMBL7901 | ||
| PharmGKB | PA165958345 | ||
| Human Metabolome Database | HMDB0015595 | ||
| DrugBank | DB04868 | ||
| PubChem: Thomson Pharma | 16505655 | ||
| PubChem | 644241 | ||
| LINCS | LSM-1099 | ||
| Nikkaji | J2.203.300J | ||
| PDBe | NIL | ||
| BindingDB | 50237710 | ||
| EPA CompTox Dashboard | DTXSID5042663 | ||
| DrugCentral | 1932 | ||
| Brenda | 135566 | 24447 | |
| ChemicalBook | CB5966228 | ||
| Guide to Pharmacology | 5697 | ||
| rxnorm | NILOTINIB HYDROCHLORIDE | TASIGNA | NILOTINIB |
| ChEBI | 52172 | ||
| ZINC | ZINC000006716957 |
